<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04161170</url>
  </required_header>
  <id_info>
    <org_study_id>2019-05-028-007</org_study_id>
    <nct_id>NCT04161170</nct_id>
  </id_info>
  <brief_title>Digital Integrated Healthcare Platform in Patients With Type 2 Diabetes</brief_title>
  <official_title>Validation of Diabetes Management Effectiveness of Digital Integrated Healthcare Platform Utilizing AI-based Dietary Management Solution and Real-time Continuous Glucose Monitoring System</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Samsung Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Samsung Medical Center</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      In this three multicenter clinical trial, investigators will study the efficacy of digital
      integrated healthcare platform and CGMS (continuous glucose monitoring system) on diabetes
      management in patients with Type 2 diabetes. The platform is based on monitoring and
      intervention by medical staff using AI (aritificial intelligence)-based diet management
      solution.

      The study group includes 3 groups; a total of 294 participants with 1:1:1 randomized
      allocation: Control group A (no intervention and conventional diabetes management with
      regular outpatiant clinic visit every 3 months), Interventional group B (applying digital
      integrated healthcare platform by themselves, no monitoring and intervention by medical
      staff), and Interventional group C (applying digital integrated healthcare platform based on
      monitoring and intervention by medical staff using AI-based diet management solution and
      applying CGMS).

      This parallel study will be conducted for 48 weeks.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The reason why it is difficult to improve the lifestyle of patients with diabetes using
      existing digital healthcare applications (apps) is that there is a limit of sustainability
      that most people do not continue to use digital healthcare apps, thus, it can be possible
      only with monitoring and intervention by medical staff.

      Not only users, but also medical staff can access integrated biometric data on the digital
      integrated healthcare platform so that individual patient-specific management systems that
      monitor and intervene can continuously motivate patients to manage themselves. Also, it could
      be a prerequisite for the successful management of patients with diabetes using digital
      healthcare apps, many existing apps have been identified as failure cases in previous
      studies. In this clinical trial, investigators will study the efficacy of digital integrated
      healthcare platform based on monitoring and intervention by medical staff using AI
      (aritifical intelligence)-based diet management solution.

      In addition, in this clinical trial, the latest medical device, real-time continuous glucose
      monitoring system (CGMS) will be applied to monitor blood glucose levels. It has been
      reported that glucose level is well controlled when the number of self blood glucose
      measurement is performed frequently, but in practice, patients have time and space limitation
      in self blood glucose measurement, and it is difficult to change the management pattern of
      patients by encouraging self blood glucose measurement. Therefore, by applying a CGMS every
      three months, not only the patient but also the medical staff can access the 24-hour blood
      glucose values, and can actively participate in the blood sugar management of the patients.
      Therefore, investigators plan to conduct clinical trial using digital integrated healthcare
      platform using AI-based diet management solution and real-time CGMS
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 20, 2019</start_date>
  <completion_date type="Anticipated">December 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">August 31, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Control group A: no intervention Interventional group B: digital integrated healthcare platform Interventional group C: digital integrated healthcare platform + CGMS apply + medical team monitoring + educational intervation</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change of HbA1c (glycated hemoglobin) at 6months from baseline</measure>
    <time_frame>Change of HbA1c (glycated hemoglobin) at 6months from baseline</time_frame>
    <description>Change of HbA1c (glycated hemoglobin) at 6months from baseline</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>HbA1c</measure>
    <time_frame>glycated hemoglobin at baseline, 3, 6, 12 months</time_frame>
    <description>glycated hemoglobin</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>number of intervention for education in interventinal group C</measure>
    <time_frame>number of intervention for education in interventinal group C at baseline, 3, 6, 12 months</time_frame>
    <description>The number of educational intervention by digital integrated healthcare platform</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>hypoglycemic events</measure>
    <time_frame>hypoglycemic events at baseline, 3, 6, 12 months</time_frame>
    <description>the number of hypoglycemic events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>adverse events</measure>
    <time_frame>adverse events at baseline, 3, 6, 12 months</time_frame>
    <description>the number and types of hypoglycemic events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>patient satisfaction questionnaire score</measure>
    <time_frame>patient satisfaction questionnaire score at baseline, 3, 6, 12 months</time_frame>
    <description>patient satisfaction questionnaire score includes 8 questions and each question has score range 0 (min) - 6 (max). For questions number 2 and 3, higher score mean worse outcome in hypoglycemia but for the rest of questions, higher scores mean better outcome in diabetes management.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>body weight</measure>
    <time_frame>body weight at baseline, 3, 6, 12 months</time_frame>
    <description>body weight</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>BMI (body mass index)</measure>
    <time_frame>BMI at baseline, 3, 6, 12 months</time_frame>
    <description>BMI (body mass index)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>body fat (%)</measure>
    <time_frame>body fat (%) at baseline, 3, 6, 12 months</time_frame>
    <description>body fat (%)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>step count</measure>
    <time_frame>average step count at baseline, 3, 6, 12 months</time_frame>
    <description>step count</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>burned calories</measure>
    <time_frame>average burned calories at baseline, 3, 6, 12 months</time_frame>
    <description>burned calories</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>walking distances</measure>
    <time_frame>average walking distances at baseline, 3, 6, 12 months</time_frame>
    <description>walking distances</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>intake calories</measure>
    <time_frame>intake calories at baseline, 3, 6, 12 months</time_frame>
    <description>intake calories</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>fasting glucose level</measure>
    <time_frame>average fasting glucose level at baseline, 3, 6, 12 months</time_frame>
    <description>fasting glucose level</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>total cholesterol level</measure>
    <time_frame>total cholesterol level at baseline, 3, 6, 12 months</time_frame>
    <description>total cholesterol level</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HDL cholesterol level</measure>
    <time_frame>HDL cholesterol level at baseline, 3, 6, 12 months</time_frame>
    <description>HDL cholesterol level</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Triglycerides level</measure>
    <time_frame>Triglycerides level at baseline, 3, 6, 12 months</time_frame>
    <description>Triglycerides level</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>LDL cholesterol level</measure>
    <time_frame>LDL cholesterol level at baseline, 3, 6, 12 months</time_frame>
    <description>LDL cholesterol level</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>mean glucose level by CGMS (continuous glucose monitoring system) in interventional group C</measure>
    <time_frame>mean glucose level by CGMS at baseline, 3, 6, 12 months</time_frame>
    <description>mean glucose level by CGMS in interventional group C</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>glycemic variability by CGMS in interventional group C</measure>
    <time_frame>glycemic variability by CGMS at baseline, 3, 6, 12 months</time_frame>
    <description>glycemic variability by CGMS in interventional group C</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>standard deviation by CGMS in interventional group C</measure>
    <time_frame>standard deviation by CGMS at baseline, 3, 6, 12 months</time_frame>
    <description>standard deviation by CGMS in interventional group C</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>average applying time of CGMS in interventional group C</measure>
    <time_frame>average applying time of CGMS at baseline, 3, 6, 12 months</time_frame>
    <description>average applying time of CGMS in interventional group C</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>time in range of &lt;54mg/dL by CGMS in interventional group C</measure>
    <time_frame>time in range of &lt;54mg/dL by CGMS at baseline, 3, 6, 12 months</time_frame>
    <description>time in range of &lt;54mg/dL by CGMS in interventional group C</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>time in range of &lt;70mg/dL by CGMS in interventional group C</measure>
    <time_frame>time in range of &lt;70mg/dL by CGMS at baseline, 3, 6, 12 months</time_frame>
    <description>time in range of &lt;70mg/dL by CGMS in interventional group C</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>time in range of 70-180 mg/dL by CGMS in interventional group C</measure>
    <time_frame>time in range of 70-180 mg/dL by CGMS at baseline, 3, 6, 12 months</time_frame>
    <description>time in range of 70-180 mg/dL by CGMS in interventional group C</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>time in range of &gt;180 mg/dL by CGMS in interventional group C</measure>
    <time_frame>time in range of &gt;180 mg/dL by CGMS at baseline, 3, 6, 12 months</time_frame>
    <description>time in range of &gt;180 mg/dL by CGMS in interventional group C</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>time in range of &gt;250 mg/dL by CGMS in interventional group C</measure>
    <time_frame>time in range of &gt;250 mg/dL by CGMS at baseline, 3, 6, 12 months</time_frame>
    <description>time in range of &gt;250 mg/dL by CGMS in interventional group C</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">294</enrollment>
  <condition>Type 2 Diabetes</condition>
  <arm_group>
    <arm_group_label>Control A</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>no intervention conventional diabetes treatment and clinic visit every 3 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Intervention B</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>apply digital integrated healthcare platform clinic visit every 3 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Intervention C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>apply digital integrated healthcare platform, CGMS, and medical team monitoring, and education clinic visit every 3 months</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Digital integrated healthcare platform</intervention_name>
    <description>Digital Integrated Healthcare Platform Utilizing AI-based Dietary Management Solution and Real-time Continuous Glucose Monitoring system</description>
    <arm_group_label>Intervention B</arm_group_label>
    <arm_group_label>Intervention C</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  19~70 aged patients with type 2 diabetes

          -  Patients who have not taken diabetic medications for more than 4 weeks and patients
             who have taken at least one type of oral hypoglycemic agents at same dosage for more
             than 12 weeks

          -  Those who have glycated hemoglobin within 7.0% to 8.5% within the last 3 months

          -  overweight or obese: BMI (body mass index) â‰¥ 23 kg / m2

          -  Those who have agreed to use medical record and participate research by applying the
             digital integrated healthcare platform

          -  Those who voluntarily signed the consent form after listening the explanation of the
             clinical trial.

        Exclusion Criteria:

          -  Diabetes other than type 2 diabetes, including type 1 diabetes and gestational
             diabetes

          -  Those who are receiving insulin or GLP-1 agonist other than oral hypoglycemic agents

          -  Uncontrolled chronic liver disease (hemochromatosis, liver cancer, autoimmune liver
             disease, cirrhosis of the liver, viral hepatitis-includes all A, B and C, Wilson's
             disease)

          -  Those with acute renal failure (up to 1.5 times higher than existing serum creatinine)

          -  Those with mental illness (schizophrenia, depression, bipolar disorder, etc.)

          -  Those who are currently taking weight loss agents

          -  Those who had alcohol or drug addiction within the last three months

          -  Those who are taking medications that may affect glucose metabolism (eg,
             corticosteroids, immunoreactive drugs, etc.)

          -  Those who are pregnant or lactating and planning to become pregnant during the
             clinical trial (women of childbearing age may agree to the contraceptive plan).

          -  Those who are deemed inappropriate for participation in clinical trials
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jae Hyeon Kim, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Samsung Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jae Hyeon Kim, MD PhD</last_name>
    <phone>+82-2-3410-1580</phone>
    <email>jaehyeonmd.kim@samsung.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Samsung Medical Center</name>
      <address>
        <city>Seoul</city>
        <zip>135-710</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jae Hyeon Kim, M.D.,Ph. D</last_name>
      <phone>82-2-3410-1580</phone>
      <email>jaehyeonmd.kim@samsung.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>November 8, 2019</study_first_submitted>
  <study_first_submitted_qc>November 8, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">November 13, 2019</study_first_posted>
  <last_update_submitted>January 14, 2020</last_update_submitted>
  <last_update_submitted_qc>January 14, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 18, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Samsung Medical Center</investigator_affiliation>
    <investigator_full_name>Jae Hyeon Kim, MD, PhD</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Continuous glucose monitoring system</keyword>
  <keyword>Artificial intelligence</keyword>
  <keyword>Diabetes</keyword>
  <keyword>Digital healthcare</keyword>
  <keyword>Education</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

